Abstract 1482P
Background
More than 80% patients of Carcinoma Gall bladder (Ca GB) present with unresectable or disseminated disease. In these patients jaundice can be very distressing leading to poor quality of life (QOL) PTBD has been advocated to palliate this but, its impact on QOL has not been adequately studied.
Methods
Prospective observational study over two years included patients of proven unresectable/disseminated Ca GB presenting with jaundice. Pre-procedure parameters were recorded and PTBD done. Quality of Life (QOL) was assessed by EORTC QLQ-C30 and BIL-21 scores prior to the treatment and after 1- month. Post procedure complications were reported. Follow up was done at 1,3 and 6 months.
Results
Study included 43 patients of unresectable/disseminated Ca GB. Median age was 52 years with 74% females. 26 patients underwent unilateral (U/L) and 17 bilateral (B/L) PTBD. 4 patients needed B/L PTBD for inadequate bilirubin fall at 4 weeks. Mean serum bilirubin was 18.3 ± 7.3 mg/dl, albumin was 2.9 ± 0.5 mg/dl and INR was 1.7 ± 1.2. Commonest indication for PTBD was pruritus (65%) and only 12% patients had cholangitis. Bilirubin level at 1 week and 1 month was 15mg/dl and 7.1 mg/dl respectively(p=0.0002). Unfortunately, EORTC QLQ-C30 QOL scores showed decline in all aspects at 1 months and 3 months. Even in BIL-21 scores although there was improvement in Jaundice scale those with anxiety, pain and side effects had decline. Most patients had morbidity related to either slippage of PTBD or peri-tubal leakage. Also, inevitability of disease progression due to lack of treatment caused significant anxiety. 4 patients expired within 30 days due to cholangitis. Survival at 1-, 3- and 6- months was 60%, 23% and 7% respectively with median survival of 38 days.
Conclusions
Although jaundice is a fairly debilitating symptom in patients with unresectable Ca GB, palliation in form of PTBD may not always lead to improvement of QOL. Psychological counselling and proper guidance in terms of care of drains as well proper pain management is imperative to provide these terminally ill patients with best supportive care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
S. Galodha.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1607P - Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 10
1608P - Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
Presenter: Michael Hofman
Session: Poster session 10
1609P - PSMA-PET and PROMISE re-define stage and risk in patients with prostate cancer
Presenter: Wolfgang Fendler
Session: Poster session 10
1610P - Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
Presenter: Andrew Armstrong
Session: Poster session 10
1611P - Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore
Presenter: Kim Nguyen Chi
Session: Poster session 10
1612P - Impact of FANCA, ATM, CDK12 alterations on survival in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: David Lorente
Session: Poster session 10
1613P - Clinically advanced prostate cancer (CAPC) featuring BRCA2 loss: A comprehensive genomic profiling (CGP) study
Presenter: Chiara Mercinelli
Session: Poster session 10
1614P - PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)
Presenter: Ravi Madan
Session: Poster session 10
1615P - A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)
Presenter: Susan Halabi
Session: Poster session 10